BRAF and neoplasm: Seventeen of the 60 tumor samples (28%) were either wild‐type for the above‐referenced genes (13/17, 76%) or harbored mutations that were not assessed in plasma using the BEAMing methodology described above (one each with NRAS G12R, NRAS G12C, PIK3CA N319K, and BRAF R603*).